The angiotensin II receptor antagonist, losartan, enhances regulator of G protein signaling 2 mRNA expression in vascular smooth muscle cells of Wistar rats

Hypertension Research : Official Journal of the Japanese Society of Hypertension
Yaqiong WuYoshio Uehara

Abstract

Angiotensin II (Ang II) reportedly enhances regulator of G-protein signaling 2 (RGS2), thus making a negative feedback loop for Ang II signal transduction. However, few studies have reported whether Ang II receptor (ATR) antagonists influence RGS2 mRNA expression. We investigated RGS2 mRNA expression when Ang II binding to ATR was blocked with Ang II subtype-1 receptor (AT1R) blockers using vascular smooth muscle cells from the thoracic aorta of male Wistar rats. RGS2 mRNA expression significantly increased with Ang II stimulation, and this increase was almost completely abolished by olmesartan, a potent AT1R-specific blocker. Ang II subtype-2 receptor (AT2R) was not involved in Ang II-mediated RGS expression. In contrast, the AT1R blocker, losartan, partially decreased Ang II-mediated RGS2 mRNA expression because this antagonist directly stimulated RGS2 mRNA expression in Ang II-free medium. EXP3174, which is an active metabolite of losartan, almost completely blunted Ang II-mediated RGS2 mRNA expression without direct stimulation of RGS2 mRNA expression. Moreover, pretreatment with olmesartan abolished Ang II-mediated RGS2 mRNA expression. Treatment with a protein kinase C inhibitor partially decreased losartan-mediated RGS2 ...Continue Reading

References

Jan 1, 1997·Hypertension·K K GriendlingR W Alexander
Apr 1, 1999·The New England Journal of Medicine·Z FarfelT Iiri
Jun 3, 2000·Annual Review of Pharmacology and Toxicology·L De VriesM G Farquhar
Mar 22, 2002·The International Journal of Biochemistry & Cell Biology·John H Kehrl, Srikumar Sinnarajah
Apr 20, 2002·Circulation Research·Junichi Sadoshima
Jun 22, 2002·Drugs·Gregory T Warner, Blair Jarvis
Feb 18, 2003·The Journal of Clinical Investigation·Scott P HeximerKendall J Blumer
Jun 18, 2003·Clinical Therapeutics·Julie A Brousil, John M Burke
Aug 30, 2005·American Journal of Hypertension·Bernard I Levy
Jul 18, 2006·Cellular Signalling·Graham LaddsJohn Davey
Nov 4, 2006·Biochimica Et Biophysica Acta·Paul A InselMartin C Michel
Feb 6, 2007·Current Opinion in Pharmacology·Thomas WielandPeter Chidiac
Aug 8, 2007·The Journal of Biological Chemistry·Patrick Osei-OwusuKendall J Blumer
Apr 16, 2008·European Journal of Pharmacology·Mariëlle C Hendriks-BalkAstrid E Alewijnse
May 9, 2014·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Chonglong WuZhice Xu
Nov 27, 2015·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Yaqiong WuYoshio Uehara

❮ Previous
Next ❯

Citations

Mar 17, 2017·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Hidenori TakahashiMakoto Araie

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atopic Dermatitis

Atopic dermatitis is a chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. Discover the latest research on atopic dermatitis here.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.